Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411454 | 0.87 | DGAT1 (0.38) | DGAT1F2RL1ALOX5APFEN1NPC1 | |
| SCHEMBL21369537 | 0.85 | NPC1 (0.31) | DGAT1NPC1 | |
| SCHEMBL30536675 | 0.85 | DGAT1 (0.36) | DGAT1F2RL1ALOX5APFEN1NPC1 | |
| SCHEMBL25367415 | 0.85 | DGAT1 (0.36) | DGAT1F2RL1ALOX5APFEN1NPC1 | |
| SCHEMBL31460489 | 0.85 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL25366051 | 0.85 | DGAT1 (0.45) | DGAT1F2RL1ALOX5APFEN1NPC1 | |
| SCHEMBL29493833 | 0.85 | DGAT1 (0.45) | DGAT1F2RL1ALOX5APFEN1NPC1 | |
| SCHEMBL30706578 | 0.79 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL31411444 | 0.79 | DGAT1 (0.36) | DGAT1F2RL1NPC1 | |
| SCHEMBL25368395 | 0.78 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | DGAT1 1567/4885F2RL1 2576/4885ALOX5AP 3194/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | DGAT1 1285/4885F2RL1 2495/4885ALOX5AP 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.